← All indications
HIV Seropositivity
Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).
Drugs by status
Phase 4 trials (5)
Phase 3 trials (5)
Phase 2 trials (14)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (13)
- Merck
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Mental Health (NIMH)
- Boston University
- Duke University
- Therapeutic Concepts
- University of Modena and Reggio Emilia
- Federal University of Rio de Janeiro
- Janssen Pharmaceutica NV
- University of Helsinki
- National Institute of Child Health and Human Development (NICHD)
- Centers for Disease Control and Prevention (CDC)
Organization Involved with Phase 3 Indications (14)
- Population Council
- Addis Ababa University
- University of London
- Harvard University
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
- Institute of Tropical Medicine, Belgium
- Slotervaart Hospital
- Drugs for Neglected Diseases Initiative
- University of Gondar
- University of Barcelona
- Muhimbili University
- Bill and Melinda Gates Foundation
- United States Agency for International Development
- Medecins Sans Frontieres
Organization Involved with Phase 2 Indications (29)
- Hemispherx Biopharma
- Agouron
- Ajinomoto
- Argos Therapeutics
- CytRx
- Friends Research Institute, Inc.
- Pacgen Biopharmaceuticals Corporation
- The Ojai Foundation
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Roma La Sapienza
- CIHR Canadian HIV Trials Network
- University of Washington
- International Vaccine Institute
- McGill University
- Monash University
- Siriraj Hospital
- Universidad de Antioquia
- University of Toronto
- Yale University
- University of California, Los Angeles
- University of Montreal
- Bamako University
- University of Massachusetts
- Vita-Salute University of Milano. Italy
- Vaccine Technologies Inc.
- Laboratorios Laproff S.A.
- Humax Pharmaceutical
- IQVIA
Organization Involved with Phase 1 Indications (13)
Organization Involved with Other Experimental Indications (10)